CBIH (Cannabis Bioscience International Holdings) NonCurrent Deferred Liabilities: $0.00 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cannabis Bioscience International Holdings NonCurrent Deferred Liabilities?

Cannabis Bioscience International Holdings CBIH +33.33% NonCurrent Deferred Liabilities is $0.00 Mil as of Feb. 2026. The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Cannabis Bioscience International Holdings's non-current deferred liabilities for the quarter that ended in Feb. 2026 was $0.00 Mil.

Cannabis Bioscience International Holdings NonCurrent Deferred Liabilities Related Terms

Cannabis Bioscience International Holdings NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Cannabis Bioscience International Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Bioscience International Holdings NonCurrent Deferred Liabilities Chart

Cannabis Bioscience International Holdings Annual Data
Trend Dec06 Dec07 May09 May10 May11 May23 May24 May25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cannabis Bioscience International Holdings Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Cannabis Bioscience International Holdings (CBIH) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Feb. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Cannabis Bioscience International Holdings and its competitors.
Is Cannabis Bioscience International Holdings' NonCurrent Deferred Liabilities too high?
Cannabis Bioscience International Holdings' current NonCurrent Deferred Liabilities is $0.00 Mil.
How does Cannabis Bioscience International Holdings' NonCurrent Deferred Liabilities compare to SXTC and UPC?
Cannabis Bioscience International Holdings' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Cannabis Bioscience International Holdings and its competitors. Cannabis Bioscience International Holdings's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Bioscience International Holdings Business Description

Address 6201 Bonhomme Road, Suite 435N, Houston, TX, USA, 77036
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.